Caryn C. Borg‐Breen, Ph.D.
Founding Partner


cborg‐breen@greengriffith.com
312.883.8040
LinkedIn
Download vCard


Caryn combines the focused, technical thinking of a Ph.D. chemist with the strategic and competitive approach of a trial lawyer. A founding partner of Green, Griffith & Borg-Breen, she is regarded by clients and colleagues alike as a key advisor who quickly synthesizes complex ideas and communicates them in compelling, straightforward language.

Caryn represents both plaintiffs and defendants in patent litigation and consultation arising under the Hatch‐Waxman Act. She has served as lead trial counsel in patent infringement litigation in the U.S. federal courts and argued appeals before the Federal Circuit. Caryn also has represented clients in inter partes review (IPR) and interference actions before the Patent Trial and Appeal Board (PTAB).

Beginning each case with a deep-dive technical analysis, Caryn offers her clients a detailed assessment of potential outcomes.

“We bring intensity and energy to every phase of our work,” Caryn says. “Digging in early really sets us apart. From our clients’ perspective, it means they have a sense from the very beginning of how something is going to go. They know we’re invested in helping them reach their goals and they understand the process for getting there. We’re partners in that process.”

Caryn also advises biotechnology, chemical and pharmaceutical companies on freedom-to-operate, due diligence, licensing and prosecution issues regarding brand and generic medicines, biologics and biosimilars, medical devices and chemical products. Clients rely on her ability to master the technical details of their products with total recall, ensuring that every aspect of their intellectual property is diligently protected and actively defended at all stages of development and market release.

Before co-founding Green, Griffith & Borg-Breen, Caryn was a partner at Leydig, Voit and Mayer, Ltd.

Education

Northwestern University, J.D., cum laude
       Northwestern University Law Review, associate editor
University of North Carolina at Chapel Hill, Ph.D., chemistry
College of William and Mary, B.S., chemistry, magna cum laude,
       Phi Beta Kappa

Professional Affiliations
  • Intellectual Property Owners Association
  • Chicago Women in IP
  • Coalition of Women’s Initiatives in Law
Court Admissions
  • State of Illinois Supreme Court
  • U.S. District Court for the Northern District of Illinois
  • U.S. Court of Appeals for the Federal Circuit
  • Registered Patent Attorney, U.S. Patent and Trademark Office, No. 52,637
Honors
  • Listed in The Best Lawyers in America© in Litigation – Patent, 2020
  • Selected as a “Notable Gen X Leader in Law,” Crain’s Chicago Business, 2019
  • Featured in Leading Lawyers Magazine Business Edition, 2018
  • Selected as a “Life Sciences Star,” LMG Life Sciences, 2018
  • Honored in “Chicago’s Notable Women Lawyers” by Crain’s Custom Media, 2018
  • Named as an “IP Star,” Managing IP, 2018-2019
  • Listed in Intellectual Asset Management’s (IAM) Patent 1000 in Litigation, 2018-2019
  • Recognized by Illinois Super Lawyers in Intellectual Property Litigation, 2016-2019
  • Selected by peers as a Leading Lawyer in Intellectual Property Law — Leading Lawyers Network, 2015-2019
  • Named in the “Illinois Rising Stars” list, as published in Illinois Super Lawyers, 2009-2010, 2012-2015
  • Honored in “Top Attorneys: Illinois Outstanding Young Woman Lawyers,” as published in Chicago Magazine, 2014
Representative Matters
  • Lipocine Inc. v. Clarus Therapeutics, Inc., 19-00622-LPS (D. Del.) – JATENZO® (oral testosterone)
  • Clarus Therapeutics, Inc. v. Lipocine Inc., 19-01566 (Fed. Cir.) – Appeal of Interference No. 106,045 (PTAB)
  • Horizon Medicines LLC v. Alkem Laboratories Ltd., 18‐01014‐LPS (D. Del.) – DUEXIS® (famotidine/ibuprofen)
  • Horizon Therapeutics, LLC v. Par Pharmaceutical Inc., et al., 18-01224-RGA (D. Del.) – RAVICTI® (glycerol phenylbutyrate)
  • Lupin Ltd. et al. v. Horizon Therapeutics, LLC, IPR2018-00459 –RAVICTI® (glycerol phenylbutyrate)
  • Par Pharmaceutical, Inc. v. Horizon Therapeutics, LLC, IPR2018-01550 –RAVICTI® (glycerol phenylbutyrate)
  • Horizon Therapeutics, LLC v. Par Pharmaceutical Inc., et al., 17-05901-KM-MAH (D.N.J.) – RAVICTI® (glycerol phenylbutyrate)
  • Horizon Therapeutics, LLC v. Lupin Ltd., et al., 17-05900-KM-MAH (D.N.J.) – RAVICTI® (glycerol phenylbutyrate)
  • Horizon Pharma Ireland Limited, et al. v. Actavis Labs. UT, Inc., 17‐2149 (Fed. Cir.) – PENNSAID® 2% (topical diclofenac)
  • Dexcel Pharma Technologies Ltd. et al. v. Apotex Corp. et al., 17‐2423‐SDW (D.N.J.) – Omeprazole DR Tablets, 20 mg (OTC)
  • Horizon Therapeutics, LLC v. Par Pharmaceutical Inc., 17-05901-KM-MAH (D.N.J.) – RAVICTI® (glycerol phenylbutyrate)
  • Horizon Therapeutics, LLC v. Lupin Ltd. et al., 17-5900-KM-MAH (D.N.J.) – RAVICTI® (glycerol phenylbutyrate)
  • Abbvie Inc., et al. v. Cipla Limited, et al., 17-1631-RGA (D. Del.) – KALETRA® (lopinavir and ritonavir tablets)
  • Lupin Ltd. et al. v. Horizon Therapeutics, LLC, IPR2017-01159, -01160 – RAVICTI® (glycerol phenylbutyrate)
  • Par Pharmaceutical Inc. v. Horizon Therapeutics, LLC, IPR2017-01767, -01768 and -01769 – RAVICTI® (glycerol phenylbutyrate)
  • Adapt Pharma, et al., and Opiant Pharmaceuticals, Inc. v. Teva Pharmaceuticals, Inc., et al., 16-07721-JLL-JAD, 17-00864, -02877, -05100, 18-05752, -09880 – NARCAN® (naloxone HCl nasal spray)
  • Adapt Pharma, et al., and Opiant Pharmaceuticals, Inc. v. Perrigo UK Finco Limited Partnership, 18-15287 – NARCAN® (naloxone HCl nasal spray)
  • Dexcel Pharma Technologies Ltd. et al. v. Dr. Reddy’s Labs., Ltd. et al., 15‐8042‐ SDW (D.N.J.) – Omeprazole DR Tablets, 20 mg (OTC)
  • Dexcel Pharma Technologies Ltd. et al. v. Sun Pharma Global FZE et al., 15‐8017‐SDW (D.N.J.) – Omeprazole DR Tablets, 20 mg (OTC)
  • Horizon Pharma Ireland Limited, et al. v. Lupin Ltd. et al., 15‐3051‐NLH; 15-5027-NLH; 15-6935-NLH; 15-7745-NLH; 16-0732-NLH; 16-5054-NLH (D.N.J.) – PENNSAID® 2% (topical diclofenac)
  • Clarus Therapeutics, Inc. v. Lipocine, et al., 15‐01004‐RGA (D. Del.) – JATENZO® (Oral Testosterone Undecanoate (LPCN 1021))
  • Clarus Therapeutics, Inc. v. Lipocine, et al., Interference No. 106,045‐JTM (PTAB) – JATENZO® (Oral Testosterone Undecanoate (LPCN 1021)
  • Horizon Pharma Ireland Limited, et al. v. Actavis Labs. UT, Inc., 14‐07992‐NLH; 15‐05025‐NLH; 15‐06131‐NLH; 15‐06989‐NLH; 15‐07742‐NLH; 16‐00645‐NLH (D.N.J.) – PENNSAID® 2% (topical diclofenac)
  • Helsinn Healthcare SA et al. v. Cipla Ltd., 14‐427‐GMS (D.Del.) – ALOXI® (palonosetron HCl injection)
  • Horizon Pharma AG, et al. v. Watson Laboratories‐Florida, 13‐5124‐JEI (D.N.J.) – RAYOS® (delayed release prednisone)
  • Merck Sharp & Dohme Corp., et al. v. Cipla Ltd., et al., 13‐04017‐JBS (D.N.J.) – SUSTIVA® (efavirenz)
  • Horizon Pharma, Inc., et al. v. Par Pharmaceutical Companies, Inc., 12‐00393‐LPS (D. Del.) – DUEXIS® (famotidine/ibuprofen)
  • Pfizer Inc. et al. v. Lupin Ltd., 12‐811‐SLR (D.Del.) – PRISTIQ® (desvenlafaxine)
  • Warner Chilcott Co., LLC v. Lupin Ltd., 11‐5048‐JAP (D.N.J.) – LO LOESTRIN® FE (norethindrone acetate/ethinyl estradiol)
  • AstraZeneca AG, et al. v. Lupin Ltd., et al., 11‐4275‐JAP (D.N.J.) – VIMOVO® (naproxen/esomeprazole)
  • Pfizer Inc. et al., v. Lupin Ltd. et al., 09‐309‐GMS (D.Del.) – LYRICA® (pregabalin)
  • Shire Canada Inc., et al. v. Natco Pharma Limited, 09‐3165‐JDG (S.D.N.Y.) – FOSRENOL® (lanthanum carbonate chewable tablet)
  • Eli Lilly & Co., et al. v. APP Pharmaceuticals, LLC, 08‐0384‐GMS (D.Del.) – ALIMTA® (pemetrexed)
  • Wyeth v. Lupin Ltd., et al., 07‐0632‐WDQ (D.Md.) – EFFEXOR® XR (venlafaxine)
  • AstraZeneca AB, et al. v. Dexcel Ltd., et al., 06‐358‐SLR (D.Del.) – PRILOSEC® OTC (omeprazole OTC)
  • Parker Hannifin Corp. v. Baldwin Filters, Inc. (N.D. Ohio 2007) – oil and fuel filters
  • Molex Incorporated v. FCI Americas Technology Inc. (D. Nev. 2007) – electrical connectors
  • FCI USA Inc. et al. v. Molex Incorporated (D. Del. 2007) – electrical connectors

Looking for a law firm that knows IP, inside and out? We're ready to listen.